As the ink dries on the US approval of Novartis' heart failure treatment Entresto, talk has quickly shifted to pricing issues, and possible outcomes-based plans, rather than the drug's very ...

近日，在FDA批准MSN实验室的Entresto仿制药一周后，诺华在华盛顿特区联邦法院对 FDA 提起诉讼，声称美国监管机构批准 Entresto 的仿制药版本是非法的。

Even as Novartis takes home a partial win in court tied to its key blockbuster Entresto, the Swiss drugmaker continues to ...

Novartis’ Entresto is on course to become the first drug to be approved in the US for a form of heart failure that is notoriously hard to treat effectively, despite missing the mark in a phase 3 ...

A multinational, randomized, double-blind trial comparing Entresto versus enalapril in 8,442 adult patients with symptomatic chronic heart failure (NYHA class II–IV) and systolic dysfunction ...

Global drugmaker Novartis will lay off 427 employees who report to the company's East Hanover headquarters this spring and ...

Swiss pharma major Novartis (NOVN: VX) is set to lay off 427 employees at its East Hanover, New Jersey, site as part of a ...

Novartis' Entresto is a drug approved for the treatment of heart failure with reduced ejection fraction. Entresto has the potential to gradually reverse the damage to the heart's structure and ...

[Jernberg 2018;1a] Medical therapy initiated before hospital discharge may include angiotensin converting enzyme inhibitors, angiotensin receptor blockers, sacubitril/valsartan (Entresto ...